EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUBJECTS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 受试者被邀请参加这项研究，因为在过去的三个月里，他们被诊断出患有1型(胰岛素依赖型)糖尿病。1型糖尿病被称为自身免疫性疾病。这意味着免疫系统的细胞错误地攻击了体内产生胰岛素的β细胞。随着免疫系统继续破坏这些细胞，制造胰岛素的能力下降，糖尿病就会发生。 这项研究的目的是找出利妥昔单抗是否可以阻止体内β细胞的持续破坏。即使利妥昔单抗有效，仍有必要注射胰岛素。然而，保持胰岛β细胞制造胰岛素的时间更长，可能会更容易使血糖(葡萄糖)水平接近正常。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Subjects are being invited to be in this study because within the past three months they have been diagnosed with type 1 (insulin dependent) diabetes mellitus. Type 1 diabetes is called an autoimmune disease. This means that cells of the immune system are mistakenly attacking the beta cells in the body that produce insulin. As the immune system continues to destroy these cells, the ability to make insulin decreases, and diabetes develops. The goal of this study is to find out whether rituximab can stop the ongoing destruction of beta cells in the body. Even if rituximab works, it will still be necessary to take insulin shots. However, keeping beta cells making insulin longer may make it easier to achieve blood sugar (glucose) levels closer to normal.